Holen Sie sich die Stockscreener-App
5.96
3.09%
-0.19
Handel nachbörslich:
5.93
-0.03
-0.50%
Schlusskurs vom Vortag:
$6.15
Offen:
$6.13
24-Stunden-Volumen:
47,507
Relative Volume:
0.95
Marktkapitalisierung:
$56.88M
Einnahmen:
$5.12M
Nettoeinkommen (Verlust:
$-67.00M
KGV:
-4.0544
EPS:
-1.47
Netto-Cashflow:
$-38.94M
1W Leistung:
-6.14%
1M Leistung:
-25.32%
6M Leistung:
-19.11%
1J Leistung:
-79.52%
1-Tages-Spanne:
$5.77
$6.5435
1-Wochen-Bereich:
$5.77
$7.40
52-Wochen-Spanne:
$3.816
$30.90
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Vergleichen Sie VRCA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.96 | 56.88M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Hochstufung | Needham | Hold → Buy |
| 2023-03-22 | Eingeleitet | Jefferies | Buy |
| 2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-24 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-24 | Eingeleitet | Needham | Buy |
| 2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program - MSN
Verrica Pharmaceuticals Inc. Ranks High in Smart Money TrackerWeekly Trading Summary & Free Safe Capital Growth Stock Tips - beatles.ru
Sentiment analysis tools applied to Verrica Pharmaceuticals Inc.CPI Data & Free Community Supported Trade Ideas - Newser
Is Verrica Pharmaceuticals Inc. trending in predictive chart modelsTake Profit & Verified Swing Trading Watchlist - Newser
Can Verrica Pharmaceuticals Inc. recover in the next quarterWeekly Stock Analysis & Daily Price Action Insights - Newser
Does Verrica Pharmaceuticals Inc. have declining or rising EPSQuarterly Market Review & Scalable Portfolio Growth Ideas - sundaytimes.kr
Real time social sentiment graph for Verrica Pharmaceuticals Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - Newser
Verrica Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Gainers & Long-Term Safe Investment Ideas - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Reliable Volume Spike Alerts - Newser
Market reaction to Verrica Pharmaceuticals Inc.’s recent newsGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Sector ETF Data Correlates with Strength in Verrica Pharmaceuticals Inc.Trade Analysis Report & Growth Oriented Trading Recommendations - sundaytimes.kr
What makes Verrica Pharmaceuticals Inc. stock price move sharply2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Historical volatility pattern of Verrica Pharmaceuticals Inc. visualized2025 Major Catalysts & Long Hold Capital Preservation Plans - Newser
Verrica Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Volume Report & Risk Adjusted Swing Trade Ideas - Newser
Verrica Pharmaceuticals shares rise 2.28% after-hours following Q2 2025 earnings call. - AInvest
Verrica Posts Profit in Fiscal Q2 - AOL.com
Verrica Pharmaceuticals stock price target raised to $20 by TD Cowen - Investing.com Canada
Verrica Pharmaceuticals Reaches Nasdaq Compliance, Q2 Revenue at $12.7M - AInvest
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript - Insider Monkey
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates - MSN
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Sees Revenue Surge in Q2 2025 - TipRanks
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewswire
Verrica Posts Profit in Fiscal Q2 - The Motley Fool
Verrica Pharmaceuticals' Q2 2025: Unpacking Contradictions in Sales Strategies, Seasonality, and Patient Access - AInvest
Verrica Pharmaceuticals (VRCA) Q2 2025 Earnings and Strategic Pipeline Catalysts: A Case for Re-Rating and Investor Re-Entry - AInvest
Earnings call transcript: Verrica Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Verrica Pharmaceuticals Q2 2025 beats EPS forecast - Investing.com
VERRICA PHARMACEUTICAL Earnings Results: $VRCA Reports Quarterly Earnings - Quiver Quantitative
Verrica Pharmaceuticals earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Verrica VRCA 2025Q2 Earnings Preview Upside Potential on Strategic Expansion Plans - AInvest
Verrica Pharmaceuticals to Report Q2 Results on August 12 - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $80.00 Average PT from Analysts - Defense World
Is Verrica Pharmaceuticals Inc. showing signs of accumulationEarnings Impact and Stock Reaction Analysis - Newser
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial - GuruFocus
Verrica Pharmaceuticals to Report Q2 2025 Financial Results and Provide Corporate Update on Aug 12, 2025. - AInvest
Verrica Pharmaceuticals to host Q2 earnings call on August 12, 2025. - AInvest
Verrica Pharmaceuticals: A Strategic Leap from Niche to Diversified Biotech Leader - AInvest
Verrica Pharmaceuticals to report second quarter 2025 financial results and provide a corporate update on August 12, 2025 - MarketScreener
Verrica Pharmaceuticals (VRCA): A Turning Point in 2025 Q2 Earnings and Strategic Momentum - AInvest
Verrica Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline - Stock Titan
Common Warts Clinical Trials, Companies, Therapeutic - openPR.com
Common Warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Ph - Barchart.com
Verrica Pharmaceuticals Inc. Consolidation Zone May Signal AccumulationTrade Setups With Clear Risk Limits Highlighted - metal.it
Published on: 2025-08-04 09:22:19 - metal.it
What drives Verrica Pharmaceuticals Inc. stock priceAchieve rapid capital gains with smart investing - Jammu Links News
What analysts say about Verrica Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - Jammu Links News
How volatile is Verrica Pharmaceuticals Inc. stock compared to the marketUnmatched profit potential - Jammu Links News
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):